Multiple myeloma Archives

Best in Biotech 18 Dec 2017

Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017

Now that we’ve got the bad news out of the way, we’re here to spread some Christmas cheer with the biggest clinical successes in biotech over the past 12 months. It’s unlikely that one whole year will ever pass without a single hiccup, especially in a field as complex as biotech. For that reason, we […]

December 18, 2017 - 9 minutesmins - By Alex Dale

News and Trends 17 Nov 2017

Welcome to the Blockbuster Club, Genmab!

Genmab has achieved $1B sales in the US of its blood cancer drug, Darzalex, setting a great example for other European biotechs to follow. Genmab has officially joined the elite of the biotech world by achieving $1B (€850M) in sales of its drug for multiple myeloma, Darzalex. The biotech will now receive milestone payments of $50M (€42M) […]

November 17, 2017 - 3 minutesmins - By Alex Dale

News and Trends 1 Mar 2017

Swedish Oncology Biotech makes a Large IPO for its Peptides

The Swedish company Oncopeptides raised €68M with its IPO on Nasdaq Stockholm, which will allow the company to push their compound into phase III trials. Oncopeptides was founded in 2000 and is focused on the development of its lead compound Ygalo. After the company started a Phase II trial in patients with late stage relapsed and refractory multiple […]

March 1, 2017 - 3 minutesmins - By Melanie De Almeida

Best in Biotech 22 Dec 2016

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here’s a list of the best success stories of 2016. Biotech is becoming a powerful driving force in medicine, providing innovative therapies that could end some of the most severe diseases. To celebrate the advances in the area of […]

December 22, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Dec 2016

How is European Immuno-Oncology fighting Blood Cancer?

From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year’s edition of the American Society of Hematology (ASH) annual meeting features immuno-oncology therapies developed by the best European biotechs, with Novartis taking the lead in the CAR-T field. The 58th ASH annual meeting is wrapping up today, after the best companies […]

December 6, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Dec 2016

Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer

PharmaMar announced positive preclinical results for an ADC candidate, showing that the traditional chemistry-based pharma companies are shifting towards the new generation of biologicals. PharmaMar is an oncology pharma in Madrid mining a vast source for drug discovery: marine organisms. The company is now pivoting to a more innovative technology with the announcement of positive […]

December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Nov 2016

Celyad’s Autologous CAR-T Therapy enters Phase Ib

Celyad has received approval to start Phase Ib trials in Belgium with its autologous CAR-T therapy, which can target 80% of tumors. After a successful Phase I in leukemia and myeloma, Celyad is ready to start a Phase Ib trial for its autologous NKR-2 in 7 cancer indications, now including solid tumors. The new trial, aimed to examine different […]

November 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Oct 2016

TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer

Adaptimmune and MSD are collaborating to test a therapy for multiple myeloma that combines some of the most promising technologies in immuno-oncology: TCR and checkpoint inhibitors. Adaptimmune is an immuno-oncology billion-euro Biotech from the British Golden Triangle. Despite some trouble with the FDA recently, the company continues to forge ahead with its promising TCR technology. Now, […]

October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Jun 2016

Key German Hospital to start a Phase I trial in TCR Cell Therapy

Medigene will make its clinical debut in TCR, in a collaboration with the Max Delbrück Centre and the Charité Hospital in Berlin. The planned Phase I trial focus on the blood cancer multiple myeloma. Based near Munich (Germany), Medigene develops different anti-cancer cell therapies, as we recently discussed in an interview with former CFO […]

June 30, 2016 - 3 minutesmins - By Denise Neves Gameiro

blood cancer disease model, multi-omics, CAR-T, oncology

News and Trends 28 May 2016

It’s Blood Cancer Day, how is Biotech fixing it?

Today is the World Blood Cancer Day, an event to show solidarity to patients and raise awareness for the need of better therapies to treat these cancers – which are still often deadly. Blood cancers can affect different type of cells in the blood. Because these cells are so close to the circulatory and immune system, […]

May 28, 2016 - 4 minutesmins - By Denise Neves Gameiro

astrazeneca acerta pharma acquitision leukemia myeloma oncology cancer1

News and Trends 21 Dec 2015

Mystery Biotech No One has Ever Heard of in Biggest Deal of the Year for $7Bn

Acerta Pharma is an elusive Netherlands based Biotech with pipelines in Blood cancer and solid tumors which has somehow wrangled the biggest Biotech deal of 2015 with Pharma Giant AstraZeneca. Acerta Pharma is a Biotech start-up founded in 2012 which combines two technology platforms in drug discovery and development with a broad target range, from […]

December 21, 2015 - 3 minutesmins - By Dani Bancroft

morphosys multiple myeloma immunooncology mor202

News and Trends 7 Dec 2015

Best-in-Class Label for Blood Cancer Trial by Billion Euro Biotech

Latest results of MorphoSys candidate for Multiple Myeloma show that it was Celgene’s loss when it abandoned the phase I/IIa trial partnership on blood cancer. Announced at the American Society of Hematology (ASH) Annual Meeting this weekend in Orlando (US), the phase I/IIa drug for blood cancer from MorphoSys has shown good tolerability for this […]

December 7, 2015 - 3 minutesmins - By Dani Bancroft

Resources

Categories

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Multiple myeloma

Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017

Welcome to the Blockbuster Club, Genmab!

Swedish Oncology Biotech makes a Large IPO for its Peptides

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

How is European Immuno-Oncology fighting Blood Cancer?

Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer

Celyad’s Autologous CAR-T Therapy enters Phase Ib

TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer

Key German Hospital to start a Phase I trial in TCR Cell Therapy

It’s Blood Cancer Day, how is Biotech fixing it?

Mystery Biotech No One has Ever Heard of in Biggest Deal of the Year for $7Bn

Best-in-Class Label for Blood Cancer Trial by Billion Euro Biotech

Subscribe to our newsletter to get the latest biotech news!

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!